VHL Antikörper

Produktnummer ABIN2854928

Es gibt 1 Publikation für dieses Produkt. Der Kaninchen Polyklonal anti-VHL Antikörper wird verwendet zum Nachweis von VHL in Proben von Human. Er wurde validiert für WB, IHC (p), IF, IP und ICC.

Kurzübersicht für VHL Antikörper (ABIN2854928)

Target: VHL (Von Hippel-Lindau Tumor Suppressor, E3 Ubiquitin Protein Ligase (VHL))

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser VHL Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunofluorescence (IF), Immunoprecipitation (IP), Immunocytochemistry (ICC)

Produktdetails anti-VHL Antikörper

Kreuzreaktivität: Human, Maus

Produktmerkmale: Rabbit Polyclonal antibody to Von Hippel Lindau (von Hippel-Lindau tumor suppressor)
Von Hippel Lindau antibody

Aufreinigung: Purified by antigen-affinity chromatography.

Immunogen: Recombinant protein encompassing a sequence within the center region of human Von Hippel Lindau. The exact sequence is proprietary.

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: WB: 1:500-1:10000. ICC/IF: 1:100-1:1000. IHC-P: 1:100-1:1000. Optimal dilutions/concentrations should be determined by the researcher. Not tested in other applications.

Kommentare:

Positive Control: Myc-DDK-tagged VHL-transfected 293T

Validation: Overexpression

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 1.27 mg/mL

Buffer: 1XPBS pH 7, 20 % Glycerol, 0.025 % ProClin 300

Konservierungsmittel: ProClin

Vorsichtsmaßnahmen: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4°C. For long-term storage, aliquot and store at -20°C or below. Avoid multiple freeze-thaw cycles.

Referenzen für anti-VHL Antikörper (ABIN2854928)

Lee, Frattini, Bansal, Castano, Sherman, Hutchinson, Bruce, Califano, Liu, Cardozo, Iavarone, Lasorella: "An ID2-dependent mechanism for VHL inactivation in cancer." in: Nature, Vol. 529, Issue 7585, pp. 172-7, (2016) (PubMed).

Details zu VHL

Target: VHL (Von Hippel-Lindau Tumor Suppressor, E3 Ubiquitin Protein Ligase (VHL))

Andere Bezeichnung: von Hippel-Lindau tumor suppressor

Hintergrund: Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. A germline mutation of this gene is the basis of familial inheritance of VHL syndrome. The protein encoded by this gene is a component of the protein complex that includes elongin B, elongin C, and cullin-2, and possesses ubiquitin ligase E3 activity. This protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. RNA polymerase II subunit POLR2G/RPB7 is also reported to be a target of this protein. Alternatively spliced transcript variants encoding distinct isoforms have been observed.

Cellular Localization: Isoform 1: Cytoplasm , Membrane, Peripheral membrane protein , Nucleus , Isoform 3: Cytoplasm

Molekulargewicht: 24 kDa

Gen-ID: 7428

UniProt: P40337

Pathways: Tube Formation, Signaling Events mediated by VEGFR1 and VEGFR2, Ubiquitin Proteasome Pathway